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life expectancy for the populations studied.
Study designs and other criteria for inclusion in the review
Not stated.
Sources searched to identify primary studies
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
4 primary studies were included.
Methods of combining primary studies
Investigation of differences between primary studies
Results of the review
The sensitivity of the PSA test was 0.875 and the specificity was 0.967. The average life expectancies for those achieving a cure were: 22.88 years for the 55-59 age group, 16.67 years for the 60-69 age group, and 9.96 years for the 70-79 year age group. For those with PC, who did not achieve a cure, the life expectancy was 3 years for all age groups. The median was taken for each age group and the average for this figure was then taken, based on the 1995 published figures of life expectancy in Japan.
Methods used to derive estimates of effectiveness
Estimates of effectiveness were also based on the authors' estimates. No specific explanation was provided.
Estimates of effectiveness and key assumptions
The 5-year survival rate for the non-screened population was 0.659 and for the screened population this was 0.83. The relative survival rate was assumed to be the same for all three age groups.
Measure of benefits used in the economic analysis
The measure of benefit was life years saved between screening and non-screening groups for PC. The model used was set forth previously as the standard guideline for socio-economic evaluations of health enterprises. This source sets the national standard in comparing the cost-effectiveness of PC screening to that of screenings for other cancer types already being carried out in Japan.
